Search Clinical Trials in the European Union

Duration
Visits
Phase
Intake methods
No Placebo
Drugs
Locations
Clinical Specialty
941-960 of 2,251 trials

Dostarlimab for Untreated Locally Advanced Rectal Cancer

We are studying the effects of dostarlimab in patients with untreated Stage II/III dMMR/MSI-H rectal cancer. The goal is to see how well it works and how safe it is for these individuals.

Rectal CancerEfficacy phase (II)11-15 visitsNo PlaceboInvestigational MedicinesPartially RemoteGastroenterologyOncology

Pleural Mesothelioma: Pembrolizumab with Chemotherapy

We are studying a combination of pembrolizumab and standard chemotherapy for patients with resectable epithelioid and biphasic pleural mesothelioma. The goal is to see if this treatment improves response rates and overall survival.

Malignant Pleural Mesothelioma1-2 yearsEfficacy phase (II)6-10 visitsNo PlaceboStandard MedicinesOncology

MEPENDAX: Axitinib and Etoposide for Pediatric Brain Tumors

We are studying a new treatment combining axitinib and oral etoposide for children and young adults with relapsing medulloblastoma or ependymoma. The goal is to find the safest dose and see if it helps improve survival.

MedulloblastomaEpendymoma>2 yearsSafety phase (I)Efficacy phase (II)≤5 visitsNo PlaceboInvestigational MedicinesNeurologyOncologyPediatrics

Ovarian and Breast Cancer: zAvatar Test Study

We are exploring whether the zAvatar test can help guide treatment decisions for patients with relapsed ovarian cancer and metastatic breast cancer. This study compares outcomes from the zAvatar test approach to standard care.

Breast CancerOvarian CancerMonitoring phase (IV)No PlaceboStandard MedicinesOncology

Bipolar Disorder Type II: Lithium vs. Lamotrigine Study

We are comparing the effects of lithium and lamotrigine on mood stabilization in people with bipolar disorder type II. The goal is to see which treatment may better reduce symptoms and improve daily functioning.

Bipolar Disorder, Type II1-2 yearsMonitoring phase (IV)≤5 visitsNo PlaceboStandard MedicinesPartially RemotePsychiatry

Hamstring Injury: Hyperbaric Oxygen Therapy Study

We are investigating whether hyperbaric oxygen therapy helps athletes and military personnel recover faster from hamstring injuries. The study will also look at safety and changes in injury over time.

Hamstring InjuryConfirmation phase (III)No PlaceboStandard MedicinesOrthopedics and Traumatology

Peyronie's Disease: Study of Bacterial Collagenase

We are testing a new bacterial collagenase injection for men with Peyronie's Disease to see if it improves penile curvature and reduces discomfort. The study will assess both safety and effectiveness of this treatment.

Peyronie's Disease>2 yearsSafety phase (I)Efficacy phase (II)11-15 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesUrology

Extensive-Stage Small Cell Lung Cancer: I-DXd with Atezolizumab

We are studying a new treatment combining I-DXd and atezolizumab, with or without carboplatin, for patients with extensive-stage small cell lung cancer. The trial aims to assess safety and effectiveness as a first-line treatment.

Extensive-stage Small Cell Lung Cancer>2 yearsSafety phase (I)Efficacy phase (II)No PlaceboInvestigational MedicinesPartially RemoteOncology

Esophageal Cancer: Ifinatamab Deruxtecan Study

We are studying Ifinatamab Deruxtecan in patients with advanced esophageal squamous cell carcinoma who have already been treated. The goal is to see if it works better than standard chemotherapy options.

Esophageal Squamous Cell CarcinomaConfirmation phase (III)6-10 visitsNo PlaceboInvestigational MedicinesCost ReimbursementOncology

Recurrent or Metastatic Solid Tumors: I-DXd Treatment Study

We are testing a new treatment called I-DXd for patients with recurrent or metastatic solid tumors. The study aims to see how well it works and how safe it is for participants.

Recurrent or Metastatic Solid Tumors>2 yearsSafety phase (I)Efficacy phase (II)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementOncology

Advanced Solid Tumors: ANV600 and Pembrolizumab Study

We are testing a new treatment, ANV600, alone and with pembrolizumab for people with advanced solid tumors. The goal is to evaluate safety and how well it may help fight cancer.

Advanced Solid Tumors>2 yearsSafety phase (I)Efficacy phase (II)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesOncology

Psoriasis Management: Proactive Drug Monitoring Study

We are comparing proactive drug monitoring to standard care for people with moderate to severe psoriasis. The goal is to see if proactive monitoring helps maintain better disease control and improves quality of life.

Moderate-to-Severe Psoriasis1-2 yearsMonitoring phase (IV)No PlaceboStandard MedicinesAllergologyDermatology

Peripheral T Cell Lymphoma: LIS1 Antibody Study

We are testing a new antibody treatment for patients with relapsed or refractory peripheral T cell lymphoma. The study aims to evaluate its safety and effectiveness in fighting this type of cancer.

Peripheral T-cell Lymphoma>2 yearsSafety phase (I)Efficacy phase (II)No PlaceboStandard MedicinesCost ReimbursementHematologyOncology

Radiprodil for Children with GRIN-related Disorder

We are studying a new medication to see if it is safe and helps reduce seizures and improve behavior in children with GRIN-related disorder. This trial aims to find the right dose and understand its effects over time.

GRIN-related Disorder>2 yearsSafety phase (I)No PlaceboInvestigational MedicinesNeurologyPediatrics

High-Risk Neuroblastoma: Dinutuximab Beta with Chemotherapy

We are studying the safety and effectiveness of combining dinutuximab beta with two chemotherapy regimens for children with newly diagnosed high-risk neuroblastoma. This research aims to improve treatment options and outcomes for these young patients.

Neuroblastoma>2 yearsSafety phase (I)Efficacy phase (II)No PlaceboStandard MedicinesHematologyOncologyPediatrics

Ulcerative Colitis: Tofacitinib for Children

We are studying whether the oral medication tofacitinib can help children with moderately to severely active ulcerative colitis achieve remission. The trial will also look at how well the medication works and how it is accepted by young patients.

Ulcerative Colitis1-2 yearsConfirmation phase (III)6-10 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesCost ReimbursementPartially RemoteGastroenterologyPediatrics

Ponatinib for Pediatric Leukemias and Solid Tumors

We are studying the safety and effectiveness of ponatinib in children with recurrent or hard-to-treat leukemias and solid tumors. This trial aims to help those who have not responded to other therapies.

Acute Myeloid LeukaemiaChronic Myeloid Leukaemia1-2 yearsSafety phase (I)Efficacy phase (II)6-10 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesCost ReimbursementPartially RemoteHematologyOncology

Sepsis Treatment: Meropenem vs. Piperacillin/Tazobactam

We are comparing two antibiotics to see which one may help critically ill adults with sepsis survive better and improve their health outcomes.

Septic ShockSepsis6-12 monthsMonitoring phase (IV)No PlaceboStandard MedicinesInfectious DiseasesInternal Medicine

Narsoplimab for Children with High-Risk Stem Cell Transplant Complications

We are studying whether narsoplimab can improve survival and safety in children with thrombotic microangiopathy after stem cell transplants. This trial will help us understand how well this treatment works and its effects on young patients.

Thrombotic Microangiopathy1-2 yearsEfficacy phase (II)16-20 visitsNo PlaceboInvestigational MedicinesCost ReimbursementHematologyPediatrics

Fabry Disease: Venglustat Tablets

We are studying whether venglustat can improve heart health in adults with Fabry disease compared to standard treatments. The trial also looks at its effects on kidney function and overall well-being.

Fabry's Disease1-2 yearsConfirmation phase (III)6-10 visitsNo PlaceboInvestigational MedicinesCardiologyHematologyInternal Medicine